Pneumococcal

Clinical Resources

Materials for Providers

Alphabetical by Title

Recommendations for Pneumococcal Vaccines Use in Children and Teens

This piece gives recommendations for pneumococcal vaccines use in children and teens who are healthy or have risk factors.

Standing Orders for Administering Pneumococcal Vaccines (PCV15, PCV20, and PPSV23) to Adults

Eligible healthcare professionals may vaccinate adults who meet any of the criteria on this form

Standing Orders for Administering Pneumococcal Vaccines to Children and Teens

Eligible healthcare professionals may vaccinate children or adolescents who meet any of the criteria on this form

Materials for Vaccine Recipients

Alphabetical by Title

Pneumococcus: Questions and Answers

Information about the disease and vaccines for patients and parents

View all Clinical Resources

CDC · FDA · State

ACIP Recommendations

Current Recommendations

ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
MMWR. 2023 / 72(39);1072
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
MMWR. 2023 / 72(RR-3);1–39
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, September 16, 2022, 71(37);1174–1181
Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, January 28, 2022, 71 (4); 109-117
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged 65 Years and older: Updated Recommendations of the Advisory Committee on Immunization Practices
MMWR, November 22, 2019; 68(46):1069–1075
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 4, 2015; 64(34):944-947
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, September 19, 2014; 63(37):822-825
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, June 28, 2013; 62(25):521-524
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR, October 12, 2012; 61(40):816-9
Prevention of Pneumococcal Disease Among Infants and Children–Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
MMWR, December 10, 2010; 59(RR11):1-18
Updated ACIP Recommendations: Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
MMWR, September 3, 2010; 59(34):1102-6

Vaccine Information Statements

Multi-vaccine VIS
Updated: July 24, 2023
PCV (Pneumococcal Conjugate) VIS
Updated: May 12, 2023
PPSV (Pneumococcal Polysaccharide) VIS
Updated: October 30, 2019

FDA Package Inserts & EUAs

Pneumococcal (PCV): Prevnar 20 Package Insert
Pfizer
Pneumococcal (PCV): Vaxneuvance (PCV15) Package Insert
Merck & Co, Inc.
Pneumococcal (PCV): Prevnar 13 Package Insert
Pfizer
Pneumococcal (PPSV): Pneumovax 23 Package Insert
Merck & Co., Inc.

More from Immunize.org

Unprotected People Stories

This page was updated on .